Abstracts tagged "transforming growth factor and treatment"

Abstract Number: 1900 • 2018 ACR/ARHP Annual Meeting
FGFR3/ FGF9 Regulates the Activity of Profibrotic Cytokine and Growth Factor Pathways to Drive Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis
Debomita Chakraborty¹, Lena Summa², Thuong Trinh-Minh³, Chih-Wei Chen³, Alina Soare², Andreas Ramming⁴, Oliver Distler⁵, Georg Schett² and Jörg Distler³, ¹Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Fibroblast growth factor receptor3 (FGFR3) is a member of the family of 4 different receptors (FGFR1-4) with more than 23 identified ligands FGF1-23. Each…
Abstract Number: 786 • 2012 ACR/ARHP Annual Meeting
Crosstalk Between Integrins and TGFβ in the Pathogenesis and Treatment of Multiple Presentations of Scleroderma
Elizabeth E. Gerber¹, Fredrick M. Wigley², Elaine C. Davis³, David L. Huso⁴ and Harry C. Dietz¹, ¹Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada, ⁴Comparative Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Scleroderma, defined as pathologic fibrosis of the skin, has many clinical presentations. In the most commonly recognized form, systemic sclerosis (SSc), previously healthy individuals…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].